

# John Harrison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11107823/publications.pdf>

Version: 2024-02-01

30  
papers

2,635  
citations

516561

16  
h-index

477173

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, efficacy, and biomarker findings of PBT2 in targeting A $\beta$ 2 as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 779-786.	4.9	657
2	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
3	Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 225-236.	1.2	256
4	Coloured Speech Perception: Is Synaesthesia what Happens when Modularity Breaks Down?. <i>Perception</i> , 1993, 22, 419-426.	0.5	232
5	Synaesthesia: Prevalence and Familiarity. <i>Perception</i> , 1996, 25, 1073-1079.	0.5	228
6	A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials. <i>Archives of Neurology</i> , 2007, 64, 1323.	4.9	189
7	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 873-881.	1.1	100
8	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. <i>Alzheimer's and Dementia</i> , 2017, 13, 186-195.	0.4	85
9	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107.	3.0	80
10	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	5.3	64
11	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 120-127.	0.9	58
12	A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B12. <i>Clinical Nutrition</i> , 2017, 36, 1509-1515.	2.3	48
13	A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. <i>Clinical Nutrition</i> , 2020, 39, 2399-2405.	2.3	48
14	Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 471-480.	1.2	44
15	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	2.0	39
16	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.	1.8	26
17	Measuring the mind: assessing cognitive change in clinical drug trials. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 471-473.	1.3	18
18	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2014, 3, 158-69.	0.1	14

#	ARTICLE	IF	CITATIONS
19	Synaesthesia: An Account of Coloured Hearing. Leonardo, 1994, 27, 343.	0.2	13
20	Synaesthesia: reconciling the subjective with the objective. Endeavour, 1995, 19, 157-160.	0.1	13
21	Cognition in MCI and Alzheimer's Disease: Baseline Data from a Longitudinal Study of the NTB. Clinical Neuropsychologist, 2014, 28, 252-268.	1.5	13
22	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 153-160.	1.2	12
23	Cognitive Approaches to Early Alzheimer's Disease Diagnosis. Medical Clinics of North America, 2013, 97, 425-438.	1.1	11
24	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). Scandinavian Journal of Pain, 2017, 15, 62-67.	0.5	11
25	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. Journal of Affective Disorders, 2018, 238, 228-232.	2.0	11
26	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. BMJ Open, 2022, 12, e052250.	0.8	7
27	Acquired and inherited forms of cross-modal correspondence. Neurocase, 1996, 2, 245-249.	0.2	5
28	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. Drug Discovery Today, 2021, 26, 1330-1336.	3.2	3
29	Acquired and Inherited Forms of Cross-modal Correspondence. Neurocase, 1996, 2, 245-249.	0.2	2
30	The Use and Development of Clinical Measures of Alzheimer's Disease Trials. , 2022, , 281-291.		0